Clinical Guidelines
Why Glaucoma Prevalence Is Rising
-
By
-
March 24, 2026
-
4 min
By
March 24, 2026
Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.
by Kerri Miller
March 24, 2026
An overview of key visual and anatomic findings with EYP-1901 from the DAVIO 2 and VERONA clinical trials, presented at Macula Society 2026
March 24, 2026
Phase 1b results for danegaptide indicate promising safety profile in patients with non-proliferative diabetic retinopathy and macular edema
March 24, 2026